Profectus Biosciences Inc., of Baltimore, said the Department of Defense's Medical Countermeasure Systems-Joint Vaccine Acquisition Program has granted it a $9.5 million contract to support manufacturing and phase I testing of its trivalent and monovalent vaccines for Ebola and Marburg viruses.